TW200626150A - Use of Epothilones in the treatment of bone metastasis - Google Patents
Use of Epothilones in the treatment of bone metastasisInfo
- Publication number
- TW200626150A TW200626150A TW094133125A TW94133125A TW200626150A TW 200626150 A TW200626150 A TW 200626150A TW 094133125 A TW094133125 A TW 094133125A TW 94133125 A TW94133125 A TW 94133125A TW 200626150 A TW200626150 A TW 200626150A
- Authority
- TW
- Taiwan
- Prior art keywords
- epothilones
- treatment
- bone metastasis
- bone
- metastasis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090377A EP1640004A1 (en) | 2004-09-24 | 2004-09-24 | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200626150A true TW200626150A (en) | 2006-08-01 |
Family
ID=34928830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094133125A TW200626150A (en) | 2004-09-24 | 2005-09-23 | Use of Epothilones in the treatment of bone metastasis |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP1640004A1 (zh) |
JP (1) | JP2008514569A (zh) |
KR (1) | KR20070054214A (zh) |
CN (1) | CN101065126A (zh) |
AR (1) | AR051035A1 (zh) |
AU (1) | AU2005287477A1 (zh) |
BR (1) | BRPI0516080A (zh) |
CA (1) | CA2580215A1 (zh) |
CR (1) | CR9064A (zh) |
EC (1) | ECSP077390A (zh) |
GT (1) | GT200500267A (zh) |
IL (1) | IL181785A0 (zh) |
MX (1) | MX2007003503A (zh) |
NO (1) | NO20072099L (zh) |
PA (1) | PA8646201A1 (zh) |
PE (1) | PE20060695A1 (zh) |
RU (1) | RU2007115162A (zh) |
TW (1) | TW200626150A (zh) |
UY (1) | UY29136A1 (zh) |
WO (1) | WO2006032537A2 (zh) |
ZA (1) | ZA200703306B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1930004A1 (en) * | 2006-12-08 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Use of epothilones in the treatment of osteoporosis and related diseases |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
AU2795000A (en) * | 1998-12-22 | 2000-07-12 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
PE20010116A1 (es) * | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
AU775373B2 (en) * | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
JP2004508810A (ja) * | 2000-04-28 | 2004-03-25 | コーサン バイオサイエンシーズ, インコーポレイテッド | ポリケチドの生成 |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
WO2002080846A2 (en) * | 2001-04-03 | 2002-10-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
KR20040106422A (ko) * | 2002-05-01 | 2004-12-17 | 노파르티스 아게 | 간암 및 다른 암 질병 치료용 에포틸론 유도체 |
EP1581218A1 (en) * | 2002-12-05 | 2005-10-05 | Schering AG | Epothilone analogs for site specific delivery in the treatment of proliferative diseases |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
EP1475105A1 (en) * | 2003-05-09 | 2004-11-10 | Schering AG | Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
CA2530311A1 (en) * | 2003-06-27 | 2005-01-06 | Novartis Ag | Cancer treatment with epothilones |
MXPA06002393A (es) * | 2003-09-02 | 2006-06-20 | Novartis Ag | Tratamiento de cancer con epotilomas. |
-
2004
- 2004-09-24 EP EP04090377A patent/EP1640004A1/en not_active Withdrawn
-
2005
- 2005-09-22 JP JP2007532855A patent/JP2008514569A/ja active Pending
- 2005-09-22 WO PCT/EP2005/010400 patent/WO2006032537A2/en active Application Filing
- 2005-09-22 RU RU2007115162/15A patent/RU2007115162A/ru not_active Application Discontinuation
- 2005-09-22 PA PA20058646201A patent/PA8646201A1/es unknown
- 2005-09-22 MX MX2007003503A patent/MX2007003503A/es not_active Application Discontinuation
- 2005-09-22 AU AU2005287477A patent/AU2005287477A1/en not_active Abandoned
- 2005-09-22 CN CNA2005800402761A patent/CN101065126A/zh active Pending
- 2005-09-22 BR BRPI0516080-4A patent/BRPI0516080A/pt not_active IP Right Cessation
- 2005-09-22 EP EP05788787A patent/EP1809281A2/en not_active Withdrawn
- 2005-09-22 KR KR1020077006651A patent/KR20070054214A/ko not_active Application Discontinuation
- 2005-09-22 CA CA002580215A patent/CA2580215A1/en not_active Abandoned
- 2005-09-23 GT GT200500267A patent/GT200500267A/es unknown
- 2005-09-23 PE PE2005001103A patent/PE20060695A1/es not_active Application Discontinuation
- 2005-09-23 UY UY29136A patent/UY29136A1/es not_active Application Discontinuation
- 2005-09-23 TW TW094133125A patent/TW200626150A/zh unknown
- 2005-09-26 AR ARP050104007A patent/AR051035A1/es unknown
-
2007
- 2007-03-07 IL IL181785A patent/IL181785A0/en unknown
- 2007-04-11 EC EC2007007390A patent/ECSP077390A/es unknown
- 2007-04-19 CR CR9064A patent/CR9064A/es not_active Application Discontinuation
- 2007-04-23 NO NO20072099A patent/NO20072099L/no not_active Application Discontinuation
- 2007-04-23 ZA ZA200703306A patent/ZA200703306B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP077390A (es) | 2007-05-30 |
BRPI0516080A (pt) | 2008-08-19 |
WO2006032537A2 (en) | 2006-03-30 |
EP1809281A2 (en) | 2007-07-25 |
NO20072099L (no) | 2007-04-23 |
PA8646201A1 (es) | 2006-11-09 |
PE20060695A1 (es) | 2006-08-03 |
AU2005287477A1 (en) | 2006-03-30 |
KR20070054214A (ko) | 2007-05-28 |
CA2580215A1 (en) | 2006-03-30 |
IL181785A0 (en) | 2007-07-04 |
CR9064A (es) | 2007-10-01 |
CN101065126A (zh) | 2007-10-31 |
EP1640004A1 (en) | 2006-03-29 |
ZA200703306B (en) | 2010-06-30 |
WO2006032537A3 (en) | 2006-05-04 |
RU2007115162A (ru) | 2008-11-20 |
MX2007003503A (es) | 2007-08-17 |
GT200500267A (es) | 2006-06-06 |
JP2008514569A (ja) | 2008-05-08 |
AR051035A1 (es) | 2006-12-13 |
UY29136A1 (es) | 2006-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200702973B (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
IL258880A (en) | Compounds of diarylhydantoin | |
HK1117422A1 (en) | Use of hif 1alfa modulators for treatment of cancer | |
MX2010000465A (es) | Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores. | |
HK1109638A1 (en) | Dr5 antibodies and uses thereof dr5 | |
SG170809A1 (en) | Diarylthiohydantoin compounds | |
IL158273A0 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
TW200612918A (en) | Lonidamine analogs | |
PL1830876T3 (pl) | Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi | |
WO2003103585A3 (en) | METHODS OF TREATING ANGIOGENESIS, TUMOR GROWTH AND METASTASES | |
HK1080840A1 (en) | Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases | |
EP1968981A4 (en) | METHOD FOR TREATING TUMORS WITH AZAXANTHONES | |
EP1934331A4 (en) | PAX2 AS A TARGET FOR THE INDUCTION OF DEFB1-MEDIATED TUMORIMMUNITY AND CANCER THERAPY | |
TW200517122A (en) | Antibodies specific for cancer associated antigen SM5-1 and uses thereof | |
TW200626150A (en) | Use of Epothilones in the treatment of bone metastasis | |
DE602006009840D1 (de) | Verwendung von prolactin in der prophylaktischen krebstherapie | |
IL164356A (en) | Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer | |
TW200616659A (en) | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-included pain | |
IL159469A0 (en) | Xenogenic oligo-or/and polyribonucleotides as agents for the treatment of malignant tumours | |
PL1962822T3 (pl) | Terapia nowotworów złośliwych | |
UA29209U (ru) | Способ хирургического лечения рака молочной железы | |
IL165440A0 (en) | Arylcarbonylpiperazines and heteroarylpiperazines and the use thereof for treating benign and malignant tumour diseases | |
WO2006071954A3 (en) | Method of treating cancer | |
MXPA02001238A (es) | Uso de la hidralazina y procanaimida en el tratamiento de cancer como reactivadores de la expresion de genes supresores de tumores. | |
TW200640948A (en) | DR5 antibodies and uses thereof |